

## Datasheet: MCA2459F

**BATCH NUMBER 157026**

<b>Description:</b>	MOUSE ANTI HUMAN CD138:FITC
<b>Specificity:</b>	CD138
<b>Other names:</b>	SYNDECAN-1
<b>Format:</b>	FITC
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	B-A38
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Human						
<b>Product Form</b>	Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid						
<b>Max Ex/Em</b>	<table border="1"> <thead> <tr> <th>Fluorophore</th> <th>Excitation Max (nm)</th> <th>Emission Max (nm)</th> </tr> </thead> <tbody> <tr> <td>FITC</td> <td>490</td> <td>525</td> </tr> </tbody> </table>	Fluorophore	Excitation Max (nm)	Emission Max (nm)	FITC	490	525
Fluorophore	Excitation Max (nm)	Emission Max (nm)					
FITC	490	525					
<b>Preparation</b>	Purified IgG prepared by ion exchange chromatography						
<b>Buffer Solution</b>	Phosphate buffered saline						
<b>Preservative</b>	0.09% Sodium Azide						
<b>Stabilisers</b>	1% Bovine Serum Albumin						
<b>Approx. Protein Concentrations</b>	IgG concentration 0.1 mg/ml						

<b>Immunogen</b>	U266 cell line.
<b>External Database Links</b>	<p><b>UniProt:</b>  <a href="#">P18827</a>    <a href="#">Related reagents</a></p> <p><b>Entrez Gene:</b>  <a href="#">6382</a>    SDC1    <a href="#">Related reagents</a></p>
<b>Synonyms</b>	SDC
<b>RRID</b>	AB_566510
<b>Fusion Partners</b>	Spleen cells from immunized Balb/c (Iffa Credo) mice were fused with cells of the mouse X63/Ag.8653 myeloma cell line.
<b>Specificity</b>	<p><b>Mouse anti human CD138 antibody, clone B-A38</b> recognizes human CD138, also known as Syndecan-1 (SDC-1). CD138 is a member of the transmembrane heparan sulfate proteoglycan family (<a href="#">O'Connell et al. 2004</a>, <a href="#">Sanderson et al. 2008</a>). It is composed of a core protein (comprising 3 domains; a short cytoplasmic domain, a transmembrane domain, and a long extracellular domain) and covalently attached heparan sulfate chains (<a href="#">Sanderson et al. 2008</a>).</p> <p>Syndecan-1 is expressed on the surface of plasma cells within the hematopoietic system and on the surface of mature epithelial cells (<a href="#">O'Connell et al. 2004</a>). It acts as an extracellular matrix receptor, involved in many cellular functions, including cell binding, cell signaling and cytoskeletal organization through cell-cell adhesion and cell-matrix adhesion (<a href="#">Sanderson et al. 2008</a>).</p>
<b>Flow Cytometry</b>	Use 10ul of the suggested working dilution to label 10 <sup>6</sup> cells in 100ul.
<b>References</b>	<ol style="list-style-type: none"> <li>Borset, M. <i>et al.</i> (1993) Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. <a href="#">Br J Haematol. 85 (3): 446-51.</a></li> <li>Du, S. <i>et al.</i> (2010) Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. <a href="#">Int J Clin Exp Pathol. 3 (4): 448-57.</a></li> <li>Kylänpää, L. <i>et al.</i> (2009) Syndecan-1 and tenascin expression in cystic tumors of the pancreas. <a href="#">JOP. 10 (4): 378-82.</a></li> <li>Beauvais, D.M. <i>et al.</i> (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. <a href="#">J Exp Med. 206: 691-705.</a></li> <li>Beauvais, D.M. and Rapraeger, A.C. (2010) Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation <a href="#">J Cell Sci. 123: 3796-807.</a></li> <li>Kim, Y.C. <i>et al.</i> (2010) Presence of <i>Porphyromonas gingivalis</i> and plasma cell dominance in gingival tissues with periodontitis. <a href="#">Oral Dis. 16: 375-81.</a></li> <li>Chang, H. <i>et al.</i> (2010) CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma. <a href="#">Haematologica. 95: 1542-7.</a></li> <li>Mahshid Y <i>et al.</i> (2009) High expression of 5-lipoxygenase in normal and malignant</li> </ol>

- mantle zone B lymphocytes. [BMC Immunol. 10: 2.](#)
9. Guedez, L. *et al.* (2005) Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors. [Blood. 105: 1660-8.](#)
10. Li, K. *et al.* (2010) Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting as an isolated nasopharyngeal mass: a case report and review of literature. [Int J Clin Exp Pathol. 4: 190-6.](#)
11. Yang, Y. *et al.* (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. [Blood. 110: 2041-8.](#)
12. Thauinat, O. *et al.* (2010) Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. [J Immunol. 185: 717-28.](#)
13. Cannizzo, E. *et al.* (2012) The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model. [Am J Clin Pathol. 137 \(3\): 377-86.](#)
14. Li, K. *et al.* (2012) A rare and unique case of aggressive IgE- $\gamma$  plasma cell myeloma in a 28-year-old woman presented initially as an orbital mass. [Hum Pathol. 43: 2376-84.](#)
15. Christianson, H.C. *et al.* (2013) Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. [Proc Natl Acad Sci U S A. 110 \(43\): 17380-5.](#)
16. Malminen, M. *et al.* (2002) Functional expression of NF1 tumor suppressor protein: association with keratin intermediate filaments during the early development of human epidermis. [BMC Dermatol. 2: 10.](#)
17. Itoua Maïga, R. *et al.* (2014) Flow cytometry assessment of *in vitro* generated CD138+ human plasma cells. [Biomed Res Int. 2014: 536482.](#)
18. Di Niro, R. *et al.* (2016) Responsive population dynamics and wide seeding into the duodenal lamina propria of transglutaminase-2-specific plasma cells in celiac disease. [Mucosal Immunol. 9 \(1\): 254-64.](#)
19. Yigit, N. *et al.* (2015) Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia. [Hum Pathol. 46 \(8\): 1217-25.](#)
20. Lum, D. & Wong, K.P. (2006) Sarcomatoid plasmacytoma: a diagnosis not often considered. [Pathology. 38 \(6\): 593-6.](#)
21. Gill, J. *et al.* (2009) A case of hyperIgG4 disease or IgG4-related sclerosing disease presenting as retroperitoneal fibrosis, chronic sclerosing sialadenitis and mediastinal lymphadenopathy. [Pathology. 41 \(3\): 297-300.](#)
22. Adepu, S. *et al.* (2015) Incipient renal transplant dysfunction associates with tubular syndecan-1 expression and shedding. [Am J Physiol Renal Physiol. 309 \(2\): F137-45.](#)
23. Hara, S. *et al.* (2016) Distribution and components of interstitial inflammation and fibrosis in IgG4-related kidney disease: Analysis of autopsy specimens [Hum Pathol. May 28 \[Epub ahead of print\]](#)
24. Hosseini, A. *et al.* (2016) Morphometric analysis of inflammation in bronchial biopsies following exposure to inhaled diesel exhaust and allergen challenge in atopic subjects. [Part Fibre Toxicol. 13: 2.](#)
25. Uenoyama, A. *et al.* (2016) Effects of C-xylopyranoside derivative on epithelial regeneration in an *in vitro* 3D oral mucosa model. [Biosci Biotechnol Biochem. 80 \(7\): 1344-55.](#)
26. Hourai, R. *et al.* (2017) IgG4-positive cell infiltration in various cardiovascular disorders

- results from histopathological analysis of surgical samples. [BMC Cardiovasc Disord. 17 \(1\): 52.](#)

27. Nagata, K. *et al.* (2017) Epstein-Barr Virus Lytic Reactivation Activates B Cells Polyclonally and Induces Activation-Induced Cytidine Deaminase Expression: A Mechanism Underlying Autoimmunity and Its Contribution to Graves' Disease. [Viral Immunol. Mar 23. \[Epub ahead of print\]](#)

28. Tran, D.N. *et al.* (2017) Polychromatic flow cytometry is more sensitive than microscopy in detecting small monoclonal plasma cell populations. [Cytometry B Clin Cytom. 92 \(2\): 136-144.](#)

29. Puchalapalli, M. *et al.* (2019) The Laminin- $\alpha$ 1 Chain-Derived Peptide, AG73, Binds to Syndecans on MDA-231 Breast Cancer Cells and Alters Filopodium Formation. [Anal Cell Pathol \(Amst\). 2019: 9192516.](#)

30. Mittal, S. *et al.* (2013) Lymphoid aggregates that resemble tertiary lymphoid organs define a specific pathological subset in metal-on-metal hip replacements. [PLoS One. 8 \(5\): e63470.](#)

31. Egeland, N.G. *et al.* (2020) MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers. [BMC Cancer. 20 \(1\): 377.](#)

32. Forsberg, P.A. *et al.* (2019) Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. [Leuk Lymphoma. 60 \(8\): 2085-7.](#)

---

#### Further Reading

1. Anttonen, A. *et al.* (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma. [Br J Cancer. 79 \(3-4\): 558-64.](#)
2. O'Connell, F.P. *et al.* (2004) CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. [Am J Clin Pathol. 121:254-63.](#)
3. Sanderson, R.D. *et al.* (2008) Syndecan-1: a dynamic regulator of the myeloma microenvironment. [Clin Exp Metastasis. 25:149-59.](#)

---

#### Storage

Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

---

#### Guarantee

12 months from date of despatch

---

#### Health And Safety Information

Material Safety Datasheet documentation #10041 available at: <https://www.bio-rad-antibodies.com/SDS/MCA2459F>  
10041

---

#### Regulatory

For research purposes only

---

## Related Products

## Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL:FITC \(MCA928F\)](#)

## Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M366950:200529'

Printed on 05 Feb 2024

---

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)